-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

605.O1.6 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Molecular pharmacology and drug resistance mechanisms in lymphoproliferative disorders

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
antibodies, Biological, ALL, AML, apoptosis, Leukemia, Non-Biological, CLL, Diseases, drug-drug interaction, Lymphoma (any), CAR-Ts, Combinations, Therapies, Hodgkin Lymphoma, Mantle Cell Lymphoma, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DNA damage, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, pharmacology, Quality Improvement , TKI, integrative -omics, molecular testing, metabolomics, molecular interactions, pathways, proteomics, signal transduction
Monday, December 7, 2020: 7:00 AM-8:30 AM
Moderators:
Scott F. Huntington, MD, MPH, Yale University School of Medicine and Nicolas Nassar, PhD, Cincinnati Children Hospital Medical Center
Disclosures:
Huntington: AbbVie: Consultancy; Astrazeneca: Honoraria; Bayer: Consultancy, Honoraria; Celgene: Consultancy, Research Funding; DTRM: Research Funding; Genentech: Consultancy; Novartis: Consultancy; Pharmacyclics: Honoraria; TG Therapeutics: Research Funding; Flatiron Health: Consultancy; BeiGene: Consultancy.
7:00 AM

Ella R Thompson, PhD, BSc1,2*, Tamia Nguyen1*, Yamuna Kankanige, PhD1,2*, Mary Ann Anderson, MBBS, PhD, FRACP, FRCPA3,4,5, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA3*, Rachel Thijssen, PhD4*, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP1,2,3*, Constantine S. Tam, MBBS, MD3,5,6*, John F. Seymour, MBBS3,5, Andrew W Roberts, MBBS3,4,5, David Alan Westerman, MBBS, FRCPA, FRACP1,2,3 and Piers Blombery, MBBS1,2,3*

1Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
4Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
5Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia
6Department of Haematology, St Vincent's Hospital, Fitzroy, Australia

7:15 AM

Simone Ferrero, MD1,2, Daniele Grimaldi, MD2*, Elena Arrigoni3*, Gian Maria Zaccaria, PhD2*, Beatrice Alessandria2*, Elisa Genuardi2*, Gabriele De Luca2*, Marco Ghislieri4*, Alice Di Rocco5*, Alessandro Re, MD6*, Vittorio Stefoni, MD, PhD7*, Federica Cavallo1,2*, Carola Boccomini, MD8*, Monica Balzarotti9*, Vittorio Ruggero Zilioli, MD10*, Gomes da Silva Maria, MD, PhD11*, Luca Arcaini12*, Anna Lia Molinari, MD13*, Filippo Ballerini, MD14*, Andres JM Ferreri, MD15, Benedetta Puccini16*, Giuseppe A. Palumbo, MD, PhD17*, Sara Galimberti, MD, PhD18*, Sergio Cortelazzo, MD19*, Antonello Di Paolo3* and Marco Ladetto, MD20

1Hematology, University of Torino and Hospital "Città della Salute e della Scienza di Torino", Torino, Italy
2Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy
3Pharmacology Unit, University of Pisa, Pisa, Italy
4Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy
5Department of Translational and Precision Medicine, Policlinico Umberto I, Roma, Italy
6ASST Spedali Civili, Brescia, ID, Italy
7Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
8Hematology Division 2, AOU "Città della Salute e della Scienza di Torino", Turin, Italy
9Department of Haematology, Istituto Clinico Humanitas, Rozzano, Italy
10Ospedale Metropolitano Niguarda, Milano, IT-MI, Italy
11Instituto Português de Oncologia - Centro de Lisboa, Departamento de Hematologia, Lisboa, Portugal
12Department of Onco-Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
13Hematology Unit, Infermi Hospital, Rimini (FC), Italy
14Clinic of Hematology, Department of Internal Medicine (DiMI), IRCCS Ospedale Policlinico San Martino, Genova, Italy
15Onco-Hematology Department, Fondazione Centro San Raffaele, Milan, Italy
16Hematology Department, University of Florence and AOU Careggi, Firenze, Italy
17Department of Medical, Surgical and Advanced Technology "G.F. Ingrassia", University of Catania, Catania, Italy
18Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy
19Clinica Humanitas/Gavazzeni, Bergamo, Italy
20Division of Hematology, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy

7:30 AM

Frank Owusu-Ansah1*, Jumana Afaghani2*, Stanley Lee3* and Justin Taylor, MD4

1Eastern Virginia Medical School, Norfolk, VA
2University of Miami Miller School of Medicine, Miami, FL
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Miami, FL

7:45 AM

Natalia Baran, PhD, MD1, Alessia Lodi, PhD2*, Yogesh Dhungana, PhD3*, Shannon RENEE Sweeney, PhD4*, Pandey Renu, PhD4*, Shelley Herbrich, PhD5, Fieke W Hoff, BSc6*, Anna Skwarska, PhD5,7*, Mecit Kaplan, MS8*, Vinitha Mary Kuruvilla, MSc5*, Antonio Cavazos, MSc5*, Marc Warmoes, PhD9*, Shanti Rojas-Sutterlin, PhD10*, Andre Haman, PhD10*, Diogo Troggian Veiga, PhD11*, Ken Furudate, DDM, PhD5*, Helen Ma, MS5*, Karine Harutyunyan, PhD5*, Wentao Yang12*, Mihai Gagea, MD PhD13*, Di Du, PhD9*, May Daher14, Luciana Melo Garcia, MD8*, Sujan Piya, PhD15, Vivian Ruvolo, MS16*, Sriram Shanmugavelandy17*, Ningping Feng, PhD18*, Jason P Gay, MS18*, Ondrej Havranek, MD, PhD19, Jared Henderson, MS20*, Katarzyna Tomczak, PhD21*, Marcin Kaminski, PhD22*, Daniel Herranz, PharmD23, Adolfo Ferrando, M.D., PhD24*, Elias Jabbour, MD5, Maria E Di Francesco, PhD18*, David T. Teachey, MD25, Terzah M. Horton, MD, PhD26, Katayoun Rezvani, MD, PhD8, Jun J. Yang, PhD12, Steven M. Kornblau, MD16, Eric Davis, MD20*, Koichi Takahashi, MD, PhD5, Michael Andreeff, MD, PhD16, Joseph R Marszalek, PhD27*, Philip Lorenzi, PhD9, Jiyang Yu, Ph.D.28*, Stefano Tiziani, PhD2, Trang Hoang, PhD10 and Marina Konopleva, MD, PhD5

1Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Department of Nutritional Sciences & Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX
3Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN
4Dell Pediatric Research Institute (DPRI), The University of Texas at Austin, Austin, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Pediatric Oncology/ Hematology, University Medical Center Groningen, Groningen, Netherlands
7Department of Genetics, Medical University of Bialystok, Bialystok, Poland
8Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
9Dept. of Bioinformatics and Computational Biology and The Proteomics and Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX
10IRIC - University of Montreal, Montreal, QC, Canada
11The Jackson Laboratory for Genomic Medicine, Farmington, CT
12Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
13Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
14Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
15Department of Leukemia, The University of Texas MD Anderson Cancer Center, Pearland, TX
16Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
17Abbvie, Lake Bluff, IL
18Institute for Applied Cancer Science and Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX
19Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic
20Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
21Department of Translational Molecular Pathology, UT M. D. Anderson Cancer Center, Houston, TX
22Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
23Cancer Institute of NJ, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
24Department of Pathology, Columbia University Medical Center, New York, NY
25Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
26Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX
27Institute for Applied Cancer Science & Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX
28Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN

8:00 AM

Jordy C.G. Van Der Zwet, MD1*, Jessica G.C.A.M. Buijs-Gladdines1*, Valentina Cordo', MSc1*, Donna Debets, MSc2*, Willem K. Smits1*, Zhongli Chen, MSc1*, Jelle Dylus3*, Guido Zaman, PhD3*, Maarten Altelaar, PhD2*, Koichi Oshima, MD, PhD4, Beat Bornhauser5*, Jean-Pierre Bourquin, MD, PhD5, Jan Cools, PhD6, Adolfo A. Ferrando, MD, PhD7, Josef Vormoor, MD, PhD1, Rob Pieters, MD, PhD, MSc1, Britta Julia Vormoor, MD8* and Jules P.P. Meijerink, PhD1

1Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
2Bijvoet Center of Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands
3Netherlands Translational Research Center, Oss, Netherlands
4Columbia University Medical Center, New York, NY
5Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
6Center for Cancer Biology, VIB-KU Leuven, Leuven, Belgium
7Institute for Cancer Genetics, Columbia University, New York, NY
8Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands

8:15 AM

Martin G. Klatt, MD1, Zhiyuan Yang, PhD2*, Jianying Liu, PhD2*, Tatyana Korontsvit, MD1*, Sung Soo Mun1*, Leila Peraro, PhD1*, Thomas J. Gardner, PhD1*, Christopher Bourne1*, Megan M. Dacek1*, Tao Dao, MD, PhD1*, Cheng Liu, PhD2* and David A. Scheinberg, MD, PhD1,3

1Memorial Sloan Kettering Cancer Center, New York, NY
2Eureka Therapeutics, Emeryville, CA
3Weill Cornell Medicine, New York, NY

*signifies non-member of ASH